[Dexcom ONE : Accès aux DT2 sous insulinothérapie non intensifiée]

In order to best meet your needs and inform you, the Federation has published news concerning the reimbursement of the Dexcom ONE device in August 2023.

The Dexcom company has just announced that Dexcom ONE is now available to people with type 2 diabetes, from the age of 2, treated with non-intensified insulin therapy (less than 3 injections per day) whose glycemic control is insufficient ( HbA1c ≥ 8%).

According to the press release issued by Dexcom, “100,000 additional diabetic patients*§ in France now have access to continuous glucose measurement (MCG), a technology that is changing the daily management of diabetes. »

The Federation welcomes this news concerning the expansion of the eligibility of this device which will allow more people with diabetes to have the choice regarding their continuous glucose measurement system (MCG).

How does this device work?

Dexcom One consists of a sensor and a transmitter that measures and sends data in real time to a compatible smartphone or receiver. The system can be placed on the back of the arm, on the abdomen or on the top of the buttocks (in children aged 2 to 17).

Expanded prescription indications

The initial prescription is 1 to 3 months: it is done by a diabetologist or a pediatrician experienced in diabetology (hospital and city) or by a general practitioner for the indication of non-intensified insulin therapy (less than 3 injections per day), including glycemic control is insufficient (HbA1c ≥ 8%). It can be renewed by any doctor.

To find out more about how to prescribe the device and your eligibility, contact your diabetologist or your general practitioner.

Sources:
Press release: Dexcom ONE is now available to type 2 diabetic patients treated with non-intensified insulin therapy from Dexcom from June 4, 2024
*§ According to the HAS opinion of January 30, 2024 modifying the registration conditions of the DEXCOM ONE continuous interstitial glucose measurement system from the company DEXCOM France DEXCOM ONE (has-sante.fr)
Order of May 21, 2024 modifying the conditions for registration of the DEXCOM ONE continuous interstitial glucose measurement system from the company DEXCOM France listed in Title I of the list of reimbursable products and services provided for in Article L. 165-1 of the social security code